Small Peptide Orexin Agonists for Wakefulness and Cataplexy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for narcolepsy and other disorders associated with orexin insufficiency, such as narcolepsy type 1, do not address the underlying cause and fail to adequately manage excessive sleepiness, cataplexy, and related symptoms.
Innovation Solution
Development of small peptide orexin receptor agonists designed to modulate orexin-2 receptor activity, offering improved physicochemical, pharmacological, and pharmaceutical properties for therapeutic potential, including specific peptide sequences that can be administered via various routes to enhance wakefulness and reduce cataplexy-like events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current approved treatments (stimulants, antidepressants) are used to manage narcolepsy symptoms, then excessive sleepiness and cataplexy can be partially addressed, but the underlying cause (orexin neuron loss) is not treated and symptoms are not adequately managed
Solution Approach 1:
The patent uses orexin receptor agonists as intermediary substances that bind to orexin receptors in the brain to restore wakefulness and suppress cataplexy. These agonists act as mediators between the lost orexin signaling and the desired therapeutic effect, providing a mechanism to compensate for orexin neuron loss without requiring regeneration of the neurons themselves.
Solution Approach 2:
The patent modifies the chemical structure and pharmacological properties of orexin receptor agonists to optimize their binding affinity, half-life, and efficacy. By changing parameters such as molecular weight, functional groups, and receptor selectivity, the compounds achieve improved therapeutic effectiveness while maintaining safety profiles.
2Reliability
If peptide agonists are designed with specific sequences and properties to enhance wakefulness, then therapeutic efficacy is improved, but the complexity of peptide design and characterization increases
Solution Approach 1:
The patent divides the peptide sequence into specific functional regions with assigned roles: certain residues are optimized for receptor binding affinity, others for metabolic stability, and others for pharmacokinetic properties. This segmentation allows systematic design and independent optimization of each functional element without redesigning the entire peptide.
Solution Approach 2:
The patent systematically varies peptide parameters such as amino acid sequence, molecular weight, charge distribution, and structural conformation to identify optimal combinations for therapeutic efficacy. Computational modeling and in silico screening are used to predict and select promising candidates before synthesis.
3Ease of operation
If alternative routes of administration (oral, intranasal, transdermal) are developed to improve bioavailability, then patient convenience is enhanced, but the complexity of formulation and delivery systems increases
Solution Approach 1:
The patent employs formulation excipients and delivery aids as intermediaries to facilitate peptide absorption across biological membranes. These intermediaries include permeation enhancers, carriers, and adjuvants that temporarily modify the peptide's interaction with tissue barriers, enabling alternative routes of administration without requiring complex device systems.
4Reliability
If high-affinity binding to orexin receptors is achieved to potentiate arousal-state regulation, then therapeutic effectiveness is enhanced, but the risk of off-target effects and safety issues increases
Solution Approach 1:
The patent optimizes the peptide's binding characteristics to achieve high affinity specifically at orexin receptors while maintaining selectivity against other receptor types. By fine-tuning local structural features such as key residue interactions and spatial configuration, the compound achieves potent orexin receptor activation without significant off-target binding, thereby reducing safety concerns.
Data Source
AI summary
The present disclosure relates to peptide having a sequence comprising:Z1X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15-NH2(Construct Number 1),And to their isomers, pharmaceutically acceptable salts, or prodrugs thereof, methods of use, and methods for their preparation. The peptides disclosed herein are useful for modulating orexin receptor activity and may be used in the treatment of disorders in which orexin receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anaesthesia.